COMP <GO>
MOH vs JNJ // FORWARD P/E MULTIPLE
Molina Healthcare Inc (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MOH 4
— JNJ 10
▲ FORWARD P/E MULTIPLE LEADER: MOH
LAST: $204.78 (+2.93%) • MKT CAP: $10.39B
forward-pe
20.5x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MOH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MOH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 13.10% | 67.90% | -54.80 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.20% | 25.50% | -8.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 18.5x | -7.10 | MOH | /valuation <GO> |
| Free Cash Flow Yield | -6.12% | 2.97% | -9.09 | JNJ | /fcf-yield <GO> |
| Operating Margin | 1.70% | 34.70% | -33.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 1.00% | 28.50% | -27.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 11.70% | 6.00% | +5.70 | MOH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.34 | 5.59 | -1.25 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.20% | -0.50 | MOH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.5 | 60.4 | -8.83 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 1.08 | -0.14 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 20.5x | 23.0x | -2.50 | MOH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.39B | $662.49B | -$652.11B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MOH REV | JNJ REV | MOH GROSS % | JNJ GROSS % | MOH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $45.43B | $94.19B | 13.1% | 67.9% | -$636.0M | $19.70B |
| FY 2024 | $40.65B | $88.82B | 15.3% | 69.1% | $544.0M | $19.84B |
| FY 2023 | $34.07B | $85.16B | 44.0% | 44.0% | $128.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MOH // BETA 0.94
JNJ // BETA 1.08